UY25050A1 - Metodo de tratamiento para diabetes mellitus - Google Patents
Metodo de tratamiento para diabetes mellitusInfo
- Publication number
- UY25050A1 UY25050A1 UY25050A UY25050A UY25050A1 UY 25050 A1 UY25050 A1 UY 25050A1 UY 25050 A UY25050 A UY 25050A UY 25050 A UY25050 A UY 25050A UY 25050 A1 UY25050 A1 UY 25050A1
- Authority
- UY
- Uruguay
- Prior art keywords
- diabetes mellitus
- treatment
- compound
- insulin
- mammal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 230000002641 glycemic effect Effects 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25050A1 true UY25050A1 (es) | 2000-09-29 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25050A UY25050A1 (es) | 1997-06-18 | 1998-06-18 | Metodo de tratamiento para diabetes mellitus |
Country Status (30)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| PT1284268E (pt) | 1999-04-23 | 2008-03-10 | Smithkline Beecham Plc | Preparação de uma forma polimórfica de um derivado de tiazolidinodiona |
| WO2000078333A2 (en) * | 1999-06-21 | 2000-12-28 | Eli Lilly And Company | Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes |
| EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| US6852694B2 (en) | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| US20020198203A1 (en) * | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and a thiazolidinedione agent |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| RU2312106C2 (ru) * | 2002-11-08 | 2007-12-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar |
| US7264813B2 (en) * | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0719140T3 (da) * | 1993-09-15 | 2008-03-03 | Daiichi Sankyo Co Ltd | Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM |
| JPH11510508A (ja) * | 1995-08-10 | 1999-09-14 | ワーナー−ランバート・コンパニー | インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法 |
| JPH11511472A (ja) * | 1995-09-18 | 1999-10-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒアゴニストを用いたｎｉｄｄｍの治療 |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Ceased
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
-
1999
- 1999-12-17 NO NO996265A patent/NO996265L/no not_active Application Discontinuation
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25050A1 (es) | Metodo de tratamiento para diabetes mellitus | |
| UY25049A1 (es) | Composiciones para tratamiento para diabetes mellitus | |
| Idris et al. | Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug | |
| EA200601145A1 (ru) | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов | |
| AR057970A2 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones | |
| NO314065B1 (no) | Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes | |
| RU98117673A (ru) | Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа | |
| BR0014142A (pt) | Composição de vacina e método de empregar a mesma | |
| BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
| WO2003075950A1 (en) | Minimising body weight gain in insulin treatment | |
| CY1105254T1 (el) | Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| AR008198A1 (es) | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona | |
| DE58906232D1 (de) | Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe. | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| UY25048A1 (es) | Composiciones para el tratamiento de la diabetes mellitus | |
| UY25051A1 (es) | Composiciones para el tratamiento de diabetes mellitus | |
| BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase | |
| PE20001239A1 (es) | Composicion de un sensibilizador de insulina | |
| PT1446404E (pt) | Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos | |
| BR0111536A (pt) | Sal de tiazolidinediona para tratamento de diabetes mellitus | |
| BR0112982A (pt) | Sal tartarato de derivado de tiazolidinadiona | |
| BR0112984A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
| Quinn | Pharmacologic management of the patient with type 2 diabetes | |
| BR0114364A (pt) | Derivado de tiazolidinediona e seu uso como anti-diabético |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090526 |